Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
INVANZ 1 g powder for concentrate for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for concentrate for solution for infusion. White to off-white powder. |
Each vial contains 1.0 g ertapenem.
Excipient with known effect: Each 1.0 g dose contains approximately 6.0 mEq of sodium (approximately 137 mg).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Ertapenem |
Ertapenem inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). In Escherichia coli, affinity is strongest to PBPs 2 and 3. |
| List of Excipients |
|---|
|
Sodium bicarbonate (E500) |
15 mL Type I glass vials with a grey butyl stopper and a white plastic cap on a coloured aluminium band seal.
Supplied in packs of 1 vial or 10 vials.
Not all pack sizes may be marketed.
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
EU/1/02/216/001
EU/1/02/216/002
Date of first authorisation: 18 April 2002
Date of latest renewal: 22 December 2011
| Drug | Countries | |
|---|---|---|
| INVANZ | Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
